SHJ
BMRN icon

Sharkey, Howes & Javer’s BioMarin Pharmaceuticals BMRN Stock Holding History

Sharkey, Howes & Javer’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-174
Closed -$14K – 250
2016
Q1 		$14K Sell
174
-188
-52% -$15.3K 0.01% 168
2015
Q4 		$38K Buy
+362
New +$37.8K 0.03% 113

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sharkey, Howes & Javer's BMRN Position: Q2 2016 in Review

Sharkey, Howes & Javer sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2016, closing a stake of 174 shares — an estimated $14K sold.

Sharkey, Howes & Javer first reported a position in BMRN in Q4 2015 and held it in 2 quarters. The position peaked at $38K in Q4 2015. 392 funds tracked by Wall St. Rank hold BMRN as of Q2 2016.

  • Sharkey, Howes & Javer reported no remaining BioMarin Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Sharkey, Howes & Javer sold 174 BioMarin Pharmaceuticals shares in Q2 2016, an estimated $14K.
  • Sharkey, Howes & Javer first reported a position in BioMarin Pharmaceuticals in Q4 2015 and held it in 2 quarters.
  • Sharkey, Howes & Javer's BioMarin Pharmaceuticals position peaked at $38K in Q4 2015.
  • 392 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2016.

Based on Sharkey, Howes & Javer's 13F filing for Q2 2016, filed 5 Aug 2016.